Pfizer Expects To File 12 "Major" NDAs By The End Of 2006
This article was originally published in The Pink Sheet Daily
The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.
You may also be interested in...
Pfizer and Boehringer Ingelheim's chronic obstructive pulmonary disease therapy Spiriva (tiotropium) has a 10% share of new prescriptions.
The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.
FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.